Legal Calls sells exclusive Keytruda injury leads and signed retainers to law firms reviewing individual claims. Claimants allege Keytruda (pembrolizumab) caused severe immune-related injuries such as myocarditis, myositis and myasthenia gravis. Leads come from our own Meta, TikTok and Google ads, are screened in-house, and are delivered by CRM, API, email or warm transfer.
| Case type | Pharmaceutical failure-to-warn claims (pembrolizumab), investigation stage |
| Litigation | No MDL; claims are filed individually against Merck |
| Alleged injuries | Immune-related myocarditis, myositis, myasthenia gravis; wrongful death |
| Lead sources | Meta, TikTok & Google ads — no affiliates |
| What you get | Exclusive leads or signed retainers |
| Delivery | CRM, API, email or warm transfer |
| Intake | In-house team, under 1-minute speed-to-lead |
| Proof | TrustedForm certificate, call recordings, ad account access |
| Volume | On request |
| Last reviewed | November 2026 |
There is no MDL or other reported consolidated proceeding for Keytruda injury claims as of November 2026. Claims are filed individually and are at an investigation stage. No bellwethers or settlements have been reported.
The notable 2026 case is Dombeck v. Merck, filed August 18, 2026 in the Southern District of Florida. It alleges a 77-year-old melanoma patient died after developing overlapping myocarditis, myositis and myasthenia gravis about 18 days after his first Keytruda dose in 2024. The complaint claims Merck failed to warn of these risks for elderly patients with autoimmune or cardiac history.
In May 2026 the FDA approved a Keytruda label revision adding myocarditis-myositis-myasthenia gravis overlap syndrome to the Warnings and Precautions section on immune-mediated reactions. Plaintiffs are cancer patients, so causation and damages are contested and each case needs individual medical-record review. Separately, the Halozyme v. Merck dispute over subcutaneous Keytruda Qlex is a patent case, not an injury case.
Sources: Keytruda wrongful death lawsuit: Merck failed to warn of fatal immune reactions (AboutLawsuits) · New Lawsuit Says Merck Cancer Drug Keytruda Caused Fla. Man’s Death (HarrisMartin) · FDA supplement approval letter, BLA 125514/S-190 (Keytruda labeling). Status as of November 2026.
Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.
Exclusive Keytruda leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.
Signed Keytruda retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.
Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.
No. As of November 2026 Keytruda injury claims are individual lawsuits, and no MDL, class action or state consolidation has been reported. The litigation is best described as an investigation stage.
Firms are reviewing severe immune-related injuries such as myocarditis, myositis and myasthenia gravis, including overlap cases with heart block, kidney injury or death. Each case is evaluated individually.
Failure to warn and negligence: that Merck did not adequately warn of severe immune reactions, especially for elderly patients with autoimmune or cardiac histories. The overlap syndrome was added to the label in May 2026.
No. Halozyme v. Merck is a patent dispute over subcutaneous Keytruda Qlex and has nothing to do with patient injuries.
Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.
Yes, for firms that want them. Because there is no MDL, we recommend individual medical-record review on every Keytruda file.
Dupixent Leads · Oxbryta Leads · Depo-Provera Leads · Mass Tort Intake · All mass tort case leads
Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.
Book a time with our VP, and he’ll walk you through pricing and strategy step by step.